dactinomycin and leuprolide

dactinomycin has been researched along with leuprolide in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Kuramoto, M; Ogawa, M; Yamashita, J	1

Other Studies

2 other study(ies) available for dactinomycin and leuprolide

Article	Year
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer, 1995, Mar-15, Volume: 75, Issue:6 Topics: Animals; Aromatase Inhibitors; Binding Sites; Cycloheximide; Dactinomycin; Drug Screening Assays, Antitumor; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Pancreatic Neoplasms; Receptors, Estrogen; Tissue Plasminogen Activator; Toremifene; Tumor Cells, Cultured	1995

Article

Year

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012

Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells.

Cancer, 1995, Mar-15, Volume: 75, Issue:6

Topics: Animals; Aromatase Inhibitors; Binding Sites; Cycloheximide; Dactinomycin; Drug Screening Assays, Antitumor; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Pancreatic Neoplasms; Receptors, Estrogen; Tissue Plasminogen Activator; Toremifene; Tumor Cells, Cultured

1995